- Home
- WHF vs LYEL Comparison
WHF vs LYEL Comparison
Compare WHF & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WHF | LYEL |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.2M | 369.4M |
| IPO Year | 2012 | 2021 |
Fundamental Metrics
Financial Performance| Metric | WHF | LYEL |
|---|---|---|
| Price | $7.53 | $33.46 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $7.75 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 177.9K | 55.7K |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | ★ 23.58% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.42 | N/A |
| Revenue | ★ $76,339,000.00 | $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.85 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.39 | $7.65 |
| 52 Week High | $11.31 | $35.16 |
Technical Indicators
Market Signals| Indicator | WHF | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 57.72 | 82.35 |
| Support Level | $7.16 | $20.59 |
| Resistance Level | $7.84 | $25.20 |
| Average True Range (ATR) | 0.18 | 2.69 |
| MACD | 0.03 | 1.16 |
| Stochastic Oscillator | 64.47 | 94.50 |
Price Performance
Historical ComparisonAbout WHF WhiteHorse Finance Inc.
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.